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It is now well established that oncogenic (high-risk) human
papillomaviruses (HPV) are a causal factor in the development
of cervical intraepithelial and invasive neoplasias (Lorincz et al,
1992; Zur Hausen, 1994; Bosch et al, 1995; Walboomers et al,
1999). Infections with high-risk HPV (HR-HPV) are associated
with a relative risk of between 8 and 11 for the development of
squamous intraepithelial lesions (SIL) and essentially low-grade
SIL (LGSIL) containing HR-HPV progress to high-grade SIL
(HGSIL) (Koutsky et al, 1992; Gaarenstroom et al, 1994). Because
of this, there is an increasing interest in using HPV DNA detection
either alone or in addition to classic cytologic examination, essen-
tially as a method for triaging women with a cytologic diagnosis of
atypical squamous cells of undetermined significance (ASCUS) in
their cervical smears (Cox et al, 1995; Wright et al, 1998; Manos
et al, 1999) and now for primary cervical screening (Cuzick et al,
1995, 1999; Clavel et al, 1998a, 1999; Meijer et al, 1998; Kuhn
et al, 2000; Ratnam et al, 2000; Schiffman et al, 2000). Never-
theless, the low sensitivity of HPV detection in previous studies
has led some authors to consider that HPV testing does not appear
to be of value for identifying women with abnormal smears who
could be safely followed up with cytology alone (Kaufman and
Adam, 1999). Moreover, the low positive predictive value and the
cost-effectiveness of HPV DNA testing have to be taken in consid-
eration for primary screening. However, HPV DNA testing in
cervical scrapes offers a diagnostic assay without the sampling
problems and subjectivity of cytology, but such an approach needs
a specific, sensitive, reliable and easy to perform method. 
5 years ago, a commercial HPV detection test, Hybrid Capture-I
(HC-I), followed by second-generation test Hybrid Capture II (HC-
II) was introduced (Lorincz, 1996). HC-II is a non-radioactive,
reproducible, relatively rapid, liquid hybridization assay in micro-
titres designed to detect 18 HPV types divided into high-risk (types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and low-risk
(types 6, 11, 42, 43 and 44) groups. The sensitivity of this assay is
quite similar to that of Polymerase Chain Reaction (PCR) (Clavel
et al, 1998b; Peyton et al, 1998; Riethmuller et al, 1999). 
Nevertheless current screening remains based on the cytopatho-
logic classification of cervical smears, according to the Bethesda
system, leading to colposcopy and histological sampling. Women
in wealthier countries are largely protected via the Papanicolaou
test. However, this test is not perfect and false-negative rates of 5
to 50% have been reported (Schneider et al, 1996; Cuzick et al,
1999). Thus, in the last few years, significant technical advances
have raised the possibility of improving conventional cytology.
Particularly, liquid-based cytology has improved sampling, fixa-
tion, staining and background, ensuring a more representative
sample with a dramatic improvement in sensitivity (Papillo et al,
1998; Sherman et al, 1998; Weintraub and Morabia, 2000). 
Recently, Cuzick et al (2000) have emphasized the urgent need to
undertake a large trial of HPV testing in conjunction with other new
technologies including liquid-based cytology. Here we report our
experience on HPV testing in primary screening of 7932 women, for
the detection of HGSIL. For that, we compared the results of HPV
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testing to the results of conventional and liquid-based cytology.
Because most LGSIL regresses spontaneously, our primary
endpoint was the histological diagnosis of HGSIL at the biopsy. 
MATERIAL AND METHODS 
Study population 
A total of 7932 women with a median age of 34 years (range 15 to
76 years) were recruited for the study between August 1997 and
February 2001. This population was restricted to women who
underwent their biennal or triennial routine screening in the
Department of Obstetrics and Gynecology of the CHU of Reims.
We excluded subjects on the basis of a recent cytologic abnor-
mality and/or an untreated cervical lesion in the past 2 years, preg-
nant women and patients with AIDS. All women were informed of
the aim of the study and gave their consent. 
Cytologic diagnosis 
At the first gynaecologic examination, in 2281 women, 2 samples
were taken: first, a cytologic smear with an Ayre’s spatula, for
classical cytology, then one scrape for the HC-II test with a
Cervexbrush (Medscan, Uppsala, Sweden). These samples were
suspended in 1 ml of specimen transport medium for HPV testing
(Digene, Silver Spring, MD). In another way, 5651 women had
only one cervical scrape with a Cervexbrush at the first entry.
Samples were prepared for liquid-based cytology with the
ThinPrep technique (Cytyc Corporation, Marlborough, Mass) and
4 ml of the sample were used for HPV testing. In total, considering
the first samples and the follow-up of women, we collected 10 101
cervical smears and scrapes. Smears were classified according to
the Bethesda system for reporting cervical or vaginal cytological
diagnosis. We selected women with adequate smears including
metaplastic and/or endocervical cells according to the criteria of
Bethesda, which represented 92% of our total smears. However,
even if the smear was not considered as adequate, we also included
women with smears evocative of lesions. In another way, 4.8% of
the samples treated for liquid-based cytology could not be used for
HPV testing and have been excluded. The cytotechnicians and
pathologists involved in the study were not informed about the
results of the HPV testing. All smears showing cytological abnor-
malities and biopsy specimens were examined by the same 2 inde-
pendent pathologists, without knowledge of cytology results for
the biopsies examination. The results were compared and if the
first 2 diagnoses disagreed, a third pathologist reviewed the case
with no knowledge of preceding diagnoses. Consensus diagnoses
were determined by two-thirds majority when possible and
remaining discrepancies resolved by conference review. Patients
with HGSIL were systematically treated by loop electrosurgical
excision procedure (LEEP). Data from these LEEP specimens
were included in the disease definitions. 
Colposcopic referral 
In our protocol (Table 1), all the women presenting cytological
abnormalities evocative of cervical lesions (from ASCUS to
HGSIL) were systematically recalled for colposcopy in the next few
weeks, at an interval ranging from 14 to 160 days (mean 95 days)
after entry examination. Punch biopsy specimens were taken from
the areas colposcopically suspicious for CIN. All the women with
smears within normal limits but presenting a HR-HPV infection
were also systematically recalled 6 months later for a new cytolog-
ical examination and HR-HPV testing followed by colposcopy if a
lesion and/or a persistent HR-HPV infection was detected. Punch
biopsy specimens were taken from the areas colposcopically suspi-
cious for CIN. The women with a second HR-HPV test positive
without any detectable lesions were recalled 6 to 12 months later for
a third control with cytological examination and HR-HPV testing
and the same indications as above for colposcopy and biopsy.
Women with regressive HR-HPV infection were also recalled for
colposcopy 12 months later. By contrast, women with initial normal
smears and without any HR-HPV infection were followed with a
classical biennal or triennal cervical screening with a new cytolog-
ical examination and HR-HPV testing at the second control. Some
of these women had also randomly a colposcopic examination.
There were not particular selection criteria for colposcopy. The
primary endpoint of our study was the detection of a histologically
proven HGSIL at the biopsy and/or on the LEEP specimen. 
HPV testing 
When conventional cytology was performed, specimens for HPV
DNA testing were suspended in 1 ml of ViraPap/Viratype transport
medium (Digene, Silver Spring, MD) and stored at –20˚C until
further processing. When samples were used for liquid based
cytology, 4 ml of the sample were centrifuged and the cell pellet was
resuspended in 200 ml of phosphate-buffered saline for HPV testing.
HPV DNA detection was performed by the commercially available
HC-II System (Digene). All scrapes were analysed for the presence
of HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.
This enzyme-linked immunosorbent assay is based on a sandwich
hybridization followed by a nonradioactive alkaline phosphatase
reaction with chemoluminescence in microplates. The chosen posi-
tive threshold of this test was 1.0 pg ml–1 of HPV DNA. 
Samples were classified as positive for HR-HPV DNA if the
relative light unit (RLU) reading obtained from the luminometer
was equal to or greater than the mean of the 3 positive control
values supplied by the HC-II kit. As some authors have reported
that increasing HPV DNA levels of HR-HPV types were the prin-
cipal predictors of CIN (Cox et al, 1995), we used as proposed, the
ratio RLU/positive controls values to quantify HR-HPV DNA in
our samples. Moreover, we added other positive controls such as
SiHa cell lines (1 to 2 copies of HPV type 16 per cell) to check the
reproducibility of the HC-II sensitivity. 
Statistical methods 
The statistical methods used were mostly descriptive. Sensitivity,
specificity, positive and negative predictive values were deter-
mined by comparing the results of each test to the gold standard of
histology. A few high-grade lesions may have been missed if they
were negative on both tests and thus women were not referred 
for colposcopy. 95% confidence interval for these values were
assessed using either binomial or normal distribution, according to
the data. Moreover, differences between HR-HPV detection and
cytologic diagnosis values were compared using Fisher exact test
or Chi-2 statistics as adequate, with a P value set to 5%. 
RESULTS 
At their first examination, in our population of 7932 women, 1214
(15.3%) presented a HR-HPV infection. 1618 C Clavel et al 
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Table 2 represents the prevalence of HR-HPV infection
observed in our 7932 women according to their age, at the first
examination. There was a peak of infection in the third
decade (23.6% of women) with a progressive decrease after 30
years. 
HPV detection and cytological and histological
diagnoses 
These results are summarized in Table 3. 
The prevalence of HR-HPV infection was significantly related
to the severity of the cytologically detected lesions (P < 0.001). 
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25 women had a smear evocative of HGSIL at the first exami-
nation with conventional cytology with a HR-HPV infection in all
of them. The diagnosis of HGSIL was histologically confirmed in
21 of them. 82 women had a smear evocative of HGSIL with
liquid-based cytology, with a HR-HPV positive test in 79 (96.3%)
of them. The diagnosis of HGSIL was confirmed by the biopsy in
58 patients who were all tested positive for HR-HPV DNA. Out of
77 women who had a smear evocative of LGSIL at the first exam-
ination with conventional cytology, 56 (72.7%) had a HR-HPV
infection. 65 of them had a follow-up and 6 had an underlying
HGSIL associated with a HR-HPV. 200 women had a smear
evocative of LGSIL with liquid-based cytology with a HR-HPV
infection in 168 (84%). In the cohort of 182 women with a follow-
up, 8 HGSIL were detected, all associated with HR-HPV. 
34 women presented ASCUS with conventional cytology with
HR-HPV in 19 of them (55.9%). In 19 women with a follow-up, 5
HGSIL were detected all tested positive for HR-HPV DNA. 175
women presented ASCUS with liquid-based cytology. HR-HPV
DNA was detected in 94 cases (53.7%). At the colposcopic control
obtained in 135 women, 6 HGSIL were diagnosed all associated
with a HR-HPV infection. 
In the remaining population of 2145 women with cervical
smears within normal limits with conventional cytology, HR-HPV
DNA was detected in 231 (10.8%). Out of these 231 women tested
HR-HPV positive, according to our protocol, 168 women (72.7%)
had a follow-up on a period from 4 to 36 months (median = 24
months). A persistent HR-HPV infection at the second and eventu-
ally third examination was observed in 66 women (39.3%) and
was associated with the detection of a HGSIL in 15 patients, 4 to
20 months after the first entry (median = 10 months). Out of 5194
women with normal smears with liquid-based cytology, 542
(10.4%) had a HR-HPV infection. In this cohort of 542 women, at
the present time, 237 women (43.7%) had a follow-up on a period
from 4 to 20 months (median = 12 months). A persistent HR-HPV
infection at the second and eventually third examination was
observed in 95 women (40.1%) and was associated with the detec-
tion of a HGSIL in 10 patients, 4 to 12 months after the first entry
(median = 6 months). No HGSIL was detected by cytology and
colposcopy in women with regressive HR-HPV infection what-
ever the initial technique of cytology used. In addition, none of the
1225 women with normal smears and without any HR-HPV infec-
tion at the first control (893 with conventional cytology and 332
with liquid-based cytology), developed HGSIL detectable at the
second systematic cytological control and at the colposcopic
examination performed in 172 of them, on a period of 24 to 36
months (median = 30 months). 
Results according to the technique of cytology and the
age of women 
Tables 4 and 5 represent the respective sensitivity, specificity,
positive and negative predictive values of the various methods
used for the detection of a HGSIL histologically proven in the
global population and in women aged >30 years. In these tables,
only results of cytology and HPV testing at the first examination
have been considered for the evaluation of these techniques, since
most women had a liquid-based cytology for their follow-up. As
expected, liquid-based cytology gave a significantly higher
sensitivity (87.8% in the general population and 84.4% in women
aged > 30 years) than conventional cytology (68.1% in the general
population and 57.7% in women aged > 30 years) (P < 0.05).
However, the sensitivity of HR-HPV testing remained higher, at
100% in all cases. Nevertheless, if the negative predictive value
was always of 100%, the specificity and the positive predictive
value of the HR-HPV testing were clearly lower than those of the
cytology whatever the technique used. Limiting the screening to
women aged > 30 years slightly increased the specificity of the
HR-HPV testing to 88.4% in scrapes treated for liquid-based
cytology and to 90.1% in smears examined with conventional
cytology, but did not modify the positive predictive value for
HGSIL detection. However, we have to emphasize that in our
same referral population, with the same follow-up protocol, 58 out
Table 2 Prevalence of high-risk HPV infections according to age at the first
examination 
Age Women High-risk HPV 
< 20 418 (5.3%) 84 (20.1%) 
21–30 1843 (23.2%) 435 (23.6%) 
31–40 2076 (26.2%) 289 (13.9%) 
41–50 1925 (24.3%) 235 (12.2%) 
51–60 1014 (12.8%) 110 (10.8%) 
> 60 656 (8.3%) 61 (9.3%) 
Total 7932 1214 (15.3%) 
Table 3 Follow-up from the first smear to the final diagnosis 
First smear HG detected First smear  HG detected
Conventional  HR-HPV  Follow-up at the Thin-prep HR-HPV Follow-up at the
cytology detection histology cytology detection histology 
2145 WL 231 168 HPV+ 15 HG 5194 WL 542 237 HPV + 10 HG 
(94.0%) (10.8%) 893 HPV – (91.9%) (10.4%) 332 HPV– 
34 ASCUS 19 19 HPV + 5 HG 175 ASCUS 94 89 HPV + 6 HG 
(1.5%) (55.9%) 7 HPV – (3.1%) (53.7%) 46 HPV – 
77 LG 56 54 HPV + 6 HG 200 LG 168 160 HPV + 8 HG 
(3.5%) (72.7%) 11 HPV – (3.5%) (84.0%) 22 HPV – 
25 HG 25 25 HPV + 21 HG 82 HG 79 79 HPV + 58 HG 
(1.1%) (100.0%) (1.4%) (96.3%) 3 HPV – 
2281 331 1177 47 HG 5651 883 968 82 HG 
WL: without lesion; LG: low-grade lesion; HG: high-grade lesion; HR-HPV: high-risk HPV. 1620 C Clavel et al 
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Table 4 Evaluation of cytology and high-risk HPV testing for the detection of histologically proven high-grade lesion 
Methods Sensitivity Specificity PPV NPV 
(95% C.I.) (95% C.I.) (95% C.I.) (95% C.I.) 
HPV detection 47/47 (100%) 1950/2234 (87.3%) 47/331 (14.2%) 1950/1950 (100%) 
93.8–100% 85.9–88.7% 10.4–18.0% 99.8–100% 
Conventional cytology 32/47 (68.1%) 2130/2234 (95.3%) 32/136 (23.5%) 2130/2145 (99.3%) 
55.4–79.2% 94.5–96.2% 16.4–30.7% 99.0–99.6% 
HPV detection 82/82 (100%) 4768/5569 (85.6%) 82/883 (9.3%) 4768/4768 (100%) 
96.4–100% 84.7–86.5% 7.4–11.2% 99.9–100% 
Thin prep cytology 72/82 (87.8%) 5184/5569 (93.1%) 72/457 (15.7%) 5184/5194 (99.8%) 
80.3–93.3% 92.4–93.8% 12.4–19.1% 99.7–99.9% 
PPV: Positive predictive value, NPV: Negative predictive value, C.I.: Confidence interval. 
Table 5 Evaluation of cytology and high-risk HPV testing for the detection of a histologically proven high-grade lesion in women
aged > 30 years 
Methods Sensitivity Specificity PPV NPV 
(95% C.I.) (95% C.I.) (95% C.I.) (95% C.I.) 
HPV detection 26/26 (100%) 1373/1524 (90.1%)  26/177 (14.7%) 1373/1373 (100%) 
89.2–100% 88.6–91.6% 9.5–19.9% 99.8–100% 
Conventional cytology 15/26 (57.7%) 1457/1524 (95.6%) 15/82 (18.3%) 1457/1468 (99.2%) 
39.1–75.0% 94.6–96.6% 9.9–26.6% 98.5–99.4% 
HPV detection 45/45 (100%) 3603/4076 (88.4%)  45/518 (8.7%) 3603/3603 (100%) 
93.6–100% 87.4–89.4% 6.3–11.1% 99.9–100% 
Thin prep cytology 38/45 (84.4%) 3863/4076 (94.8%)  38/251 (15.1%) 3863/3870 (99.8%) 
73.2–92.8% 94.1–95.5% 10.7–19.6% 99.5–99.8% 
PPV: Positive predictive value, NPV: Negative predictive value, C.I.: Confidence Interval. 
Table 6 Evaluation of the viral load (VL) estimated by the HC-II assay for the detection of a high-grade lesion in cytologically
normal smears 
Methods VL Sensitivity Specificity PPV NPV 
HPV testing associated  >3 15/15 (100%) 53/216 (24.5%)  15/178 (8.4%) 53/53 (100%) 
with conventional cytology 
>10 15/15 (100%) 88/216 (40.7%)  15/143 (10.5%) 88/88 (100%) 
HPV testing associated  >3  10/10 (100%) 203/532 (38.1%) 10/329 (2.9%)  203/203 (100%) 
with thin prep cytology
>10 7/10 (70%) 313/532 (58.8%)  7/226 (3.1%) 313/316 (99.0%) 
PPV: Positive predictive value; NPV: Negative predictive value. 
Table 7 Evaluation of cytology and high-risk HPV testing for the detection of a histologically proven high-grade lesion in function
of the viral load (VL) 
Methods Sensitivity Specificity PPV NPV 
(95% C.I.) (95% C.I.) (95% C.I.)  (95% C.I.) 
HPV detection. VL>3 44/47 (93.6%)  2008/2234 (89.9%) 44/270 (16.3%) 2008/2011 (99.8%) 
83.5–98.6% 88.6–91.1% 11.2–20.7% 99.6–99.7% 
HPV detection. VL>10 42/47 (89.4%)  2049/2234 (91.7%) 42/227 (18.5%) 2049/2054 (99.7%) 
78.4–96.1% 90.6–92.9% 13.5–23.6% 99.5–99.9% 
Conventional cytology 32/47 (68.1%)  2130/2234 (95.3%) 32/136 (23.5%) 2130/2145 (99.3%) 
55.4–79.2% 94.5–96.2% 16.4–30.7% 99.0–99.6% 
HPV detection. VL>3 80/82 (97.6%)  5007/5569 (89.9%) 80/642 (12.5%) 5007/5009 (99.9%) 
91.9–99.7% 89.1–90.7% 9.9–15.0% 99.8–99.9% 
HPV detection. VL>10 72/82 (87.8%)  5137/5569 (92.2%) 72/504 (14.3%) 5137/5147 (99.8%) 
80.3–93.3% 91.6–92.9% 11.2–17.3% 99.7–99.9% 
Thin prep cytology 72/82 (87.8%) 5184/5569 (93.1%)  72/457 (15.7%) 5184/5194 (99.8%) 
80.3–93.3% 92.4–93.8% 12.4–19.1% 99.7–99.9% 
PPV: Positive predictive value; NPV: Negative predictive value; C.I.: Confidence interval. HPV testing for primary cervical screening 1621
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of 129 HGSIL (45.0%) were detected in women aged < 30 years.
This finding explains the absence of modification of the positive
predictive value after 30 years. 
Value of the semi-quantitative viral load estimated by
the HC-II assay for predicting the persistence of 
HR-HPV infection and the apparition of HGSIL 
Table 6 represents the evaluation of different viral load estimated
in RLU (3 and 10 RLU) by the HC-II assay for predicting the
detection of HGSIL in smears within normal limits at the first
cytological examination with conventional and liquid-based
cytology. The sensitivities remained high but the specificities were
very low in any case. Table 7 evaluates the efficiency of different
viral load values (1,3 and 10 RLU) for general screening. The use
of a viral load > 10 increased specificities and predictive positive
values and the sensitivity of the HPV testing remained very high,
equivalent or superior to that of cytology. 
DISCUSSION 
This work using the HC-II assay on a series of 7932 French
women attending routine cytologic screening clearly confirms the
high prevalence of HR-HPV infection with a peak at 23.6% in the
third decade and a progressive decrease after 30 years. In the same
way, Herrero et al (2000) using PCR have reported such a high
prevalence of HPV infection in women under 25 years in rural
Costa Rica. The high percentage of women tested positive in our
cohort may partly be due to the technique used with the possibility
of cross-hybridization with unknown and/or additional HPV types
not included in the HC-II assay probe cocktails (Vernon et al,
2000), which may increase the number of positive results. There is
also a significant prevalence and/or persistence of HR-HPV infec-
tion in women with HGSIL. HR-HPV DNA has been detected in
all the 129 women with a HGSIL histologically confirmed. Thus,
in our experience at the present time, whatever the collection
protocol used for HPV testing, the sensitivity of HC-II for
detecting HGSIL is 100%, but the specificity remains low, at
87.6% when the initial sample has been associated with conven-
tional cytology, and at 85.6% when the initial sample has been
treated for liquid-based cytology, with positive predictive values
of 14.2% and 9.3% respectively. These results are quite similar to
those of previous studies using HPV testing with HC-II for
primary screening (Cuzick et al, 1999; Schiffman et al, 2000).
Moreover, in our work, the sensitivity of liquid-based cytology is
also significantly higher than that of conventional cytology
(87.8% vs 68.1%) (P < 0.05) as previously reported in the litera-
ture when the ThinPrep method has been compared to conventional
cytology (Papillo et al, 1998; Sherman et al, 1998; Weintraub and
Morabia, 2000). However, if liquid-based cytology alone is a very
efficient method, HR-HPV testing combined with cytology signif-
icantly increases the detection of HGSIL. 
The use of HPV testing for triage test in smears evocative of
ASCUS and LGSIL has been recently discussed in large series.
Adam et al (1998) have found that screening for HPV DNA with
PCR, does not have prognostic value in women reported as
having ASCUS or smears evocative of low-grade lesions. The
ALTS group (2000) has considered that, because a very high
percentage of women with cytological evidence of LGSIL are
positive for HPV DNA with the HC-II assay, there is limited
potential for HPV testing to direct decisions about the clinical
management of these women. Indeed in our series, HR-HPV
infection is frequent in this population of women (80.9%). In
consequence, its use as a discriminating test for colposcopic
referral seems of limited interest, even though all the HGSIL
detected at the histological control of cytological LGSIL, were
positive for HR-HPV DNA. In another way, in the literature,
about 50% of smears with ASCUS are tested positive for HR-
HPV DNA and 5 to 10% of ASCUS correspond to an underlying
HGSIL associated with HR-HPV infection. Thus, Manos et al
(1999) and the ALTS group (Solomon et al, 2001) have proposed
that, for women with ASCUS, HPV DNA testing can help to
identify those who have underlying HGSIL. Our results are in
agreement with this proposition since 5 HGSIL have been
detected at the colpo-histological control of ASCUS obtained in
26 women with initial conventional cytology and 6 HGSIL in 135
women with liquid-based cytology, all associated with high-risk
HPV infection. If we consider the negative predictive value of the
HC-II assay of 100%, HPV testing is a reliable test to select
women with ASCUS and HR-HPV infection who had to be
referred for colposcopy. 
In our series, we have observed that in total, 773 out of 7339
women with smears within normal limits presented a HR-HPV
infection. These numerous positive results, particularly in women
< 30 years old, are largely responsible for the low specificity and
positive predictive value of the HPV testing. Numerous HPV
infections are known to regress spontaneously, especially in young
women and the mean HPV infection duration is between 8 to 14
months (Ho et al, 1998; Franco et al, 1999). However, Rozendaal
et al (1996) have emphasized that the women with normal smears
and HR-HPV genotypes are 116 times more at risk of developing
HGSIL, in contrast of women without HR-HPV. Moreover, the
persistence of HR-HPV infection is significantly associated with
progressive disease (Ho et al, 1995; Remmink et al, 1995). Indeed,
in our follow-up of 168 (72.7%) of 231 women with smears within
normal limits with conventional cytology and with HR-HPV
infection, 15 (22.7%) out of 66 women with persistent HR-HPV
infection have presented a HGSIL within 4 to 20 months after the
first entry. At the present time, we have a shorter follow-up of only
237 (43.7%) out of 542 women with normal smears with liquid-
based cytology and HR-HPV infection and the number of 10
HGSIL detected may not exactly reflect the total HGSIL present in
this population, but these preliminary data are also very promising.
In another way, our more frequent follow-up of women with
normal smears and HR-HPV positive, induces a bias of selection
which logically results in more numerous diagnoses of HGSIL.
However, practically, a systematic intensive follow-up in parallel
of women with normal smears and without any HR-HPV infec-
tion, is difficult to propose and to obtain. Nevertheless, we
underline that no HGSIL has been detected in our cohort of 1225
women with initial HR-HPV negative and normal smears,
followed with classic biennal or triennal screening. Thus,
according to our protocol of follow-up, the detection of a persis-
tent HR-HPV infection selects a population of women with normal
smears at risk for developing a HGSIL. 
Considering that HPV infection in younger women often
spontaneously regress and that the incidence of cervical cancer
in women younger than 30 years is very low, numerous authors
(Wright et al, 1998; Cuzick et al, 1999; Stoler, 2000) have
recommended the use of HPV testing for older women (>30–35
years old). This could improve the specificity and the positive
predictive value of the test. Nevertheless, these propositions do1622 C Clavel et al 
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not consider the frequent early age of the first sexual intercourse
as a source of HPV infection with a higher risk for developing a
HGSIL before 30 years. In our experience, if we reserve HPV
testing in women > 30 years old, the positive predictive value of
HPV testing is not modified, but the specificity slightly
increases from 87.3% to 90.1% in samples associated with
conventional cytology and from 85.6% to 88.4% in samples
treated for liquid-based cytology. Again, we have to emphasize
that 58 out of our 129 patients (45.0%) with HGSIL were women
< 30 years old. This clearly explains the absence of modification
of the predictive positive values after 30 years. Consequently,
limiting HPV testing in women > 30 years in primary screening
will miss the increasing number of HGSIL present under this
age. 
There may be utility in semiquantitative measurement of high
viral load to increase the specificity of HPV testing. Indeed,
Cuzick et al (1994) have shown that in women with cytologic
abnormalities, HPV type 16 positivity at a high-level detected by a
semi-quantitative PCR is strongly related to HGSIL. Ho et al
(1995) have also suggested that SIL with a high viral load are more
likely to persist than those with a low level of HPV DNA. A recent
study using a sensitive real time quantitative PCR assay has clearly
demonstrated that cervical carcinoma in situ associated with HPV
type 16 occurs mainly in HPV type 16 positive women who had
consistently high viral loads long term (Ylitalo et al, 2000). Thus,
a high viral load may be considered as a risk factor and preferen-
tially observed in potentially evolutive lesions and in HGSIL. This
parameter could be semi-quantitatively evaluated by the relative
light unit values (RLU) provided by the HC-II assay. Our present
results with HC-II show that when this parameter is basically
applied for predicting the apparition of a HGSIL in women
without any detectable lesions, the specificity is very low <60%
but the sensitivity remains very good. Indeed for a cervical
sample/positive control ratio >10, the best results are obtained
when HPV testing is performed with conventional cytology, with a
sensitivity for predicing a HGSIL of 100%, but with a specificity
of 40.7% and a predictive positive value of 10.5%. In another way,
when a viral load >10 is considered for general screening, the
specificities and predicitive positive values increase and the sensi-
tivity is equivalent or better to that of liquid-based cytology for
detecting a HGSIL. However we have to underline that the values
of viral load are semi-quantitative global measurements for detec-
tion of one or multiple HPV types among the 13 in the kit.
Recently, Liaw et al (2001) have reported that HPV type 16 infec-
tion is generally associated with an increased risk of subsequent
acquisition of other types, but does not affect the persistence of
these concomitant infections, regardless of type. Thus, the global
high viral load detected by HC-II may be rather confusing,
reflecting multiple infections which may regress for many of them.
Moreover better viral load measurement has to be validated with a
standard denominator of number of epithelial cells collected. All
these drawbacks limit at the present time the use of viral load
provided by HC-II for predicting HGSIL. 
Of particular interest is the negative predictive value of 100%
obtained in all our series when HPV testing was used for the
screening of HGSIL. Clearly, 1225 women with normal smears
and without HR-HPV infection did not develop any detectable
HGSIL with a median follow-up of 30 months. Thus, HR-HPV
detection appears as a reliable predictive test with possible clin-
ical applications. Cytology will likely continue to be the major
screening method for the detection of cervical lesions, but it needs
a good technical approach and a high professional skill to be
highly sensitive. Considering that the mean time from detectable
LGSIL to preclinical invasive cancer is 12–13 years (Gustafson
and Adami, 1989), Meijer et al (1998) have proposed that women
with cytologically normal smears and a negative HR-HPV test
could be rescreened every 8 years. If we subscribe to this
screening policy, HPV testing combined with cytology would
significantly lower the number of cervical smears and the inci-
dence of colposcopy with a more efficient screening. Another
proposition is to begin the primary cervical screening with HPV
detection. This policy has been proposed in low-resource settings
where HPV DNA testing programmes may be easier to implement
than cytologic screening (Kuhn et al, 2000; Schiffman et al,
2000). In our wealthier countries, we can use the same cervical
scrape for HPV testing and liquid-based cytology. HR-HPV
testing would allow to select positive samples treated in a second
time for liquid-based cytology which gives a better sensitivity
than conventional cytology and a good specificity. Women with
cervical abnormalities in their smears will be immediately
recalled for colposcopy. A more intensive cytological screening
with HPV positive women with normal smears, with an algorithm
of 6 to 12 months, to confirm the persistence of HPV infection
and/or the occurrence of SIL. All these propositions of new
managements for the cervical screening require extensive and
multicentric studies in different countries to be validated in terms
of efficiency and costs–benefits. In any case, the introduction of
the HPV testing represents a new promising technology for
primary cervical screening. 
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